Andere talen ProQR Therapeutics N.V.

Aandelen

PRQR

NL0010872495

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 29-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,97 ^USD	+1,55%		-1,50%	-0,51%

14/03	PROQR THERAPEUTICS N.V. : Chardan Research ontvangt een koopadvies	ZM
13/03	ProQR Therapeutics N.V. rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

ProQR Highlights Upcoming Presentations on Axiomer RNA Editing at ASGCT 27th Annual Meeting	23/04
ProQR Therapeutics N : AGM 2024 Notice and Agenda	23/04
ProQR Therapeutics N : AGM 2024 AoA one-tier Board English redline	23/04
ProQR Therapeutics N : AGM 2024 AoA one-tier Board English clean	23/04
ProQR Therapeutics N : AGM 2024 Board Compensation Policy one-tier Board	23/04
ProQR Therapeutics N : AGM 2024 Equity Incentive Plan one-tier Board redline	23/04
ProQR Therapeutics N : AGM 2024 Equity Incentive Plan one-tier Board clean	23/04
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024	23/04
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting	22/04
ProQR Therapeutics N : AGM 2024 Explanatory Notes	22/04
ProQR Therapeutics N : AGM 2024 POA Registered Shareholders	22/04
ProQR Achieves Successful Defense of New Challenge to its Axiomer IP Portfolio	22/04
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio	19/04
ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
ProQR Announces Year End 2023 Operating and Financial Results	13/03
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing	15/02
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024	19/01
ProQR Therapeutics N.V. and Rett Syndrome Research Trust Join Forces with Axiomer RNA Editing Collaboration	05/01
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration	05/01
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration	05/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen ProQR Therapeutics N.V.

Aandelen

PRQR

NL0010872495

Andere talen

Filters